Immune Pharmaceuticals:

Developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases.

Download Investor Presentation

Committed to Bringing New Hope to Patients Living with Bullous Pemphigoid

Targeting the Immune System to Treat Inflammatory Skin Diseases

BERTILIMUMAB

Bertilimumab is a first-in-class, human monoclonal antibody that targets eotaxin-1, a chemokine that plays a role in both innate and adaptive immune responses and modulates the cross-talk between key cells involved in inflammation. Chemokines are small proteins that act as chemical attractants of inflammatory cells to sites of inflammation and infection.

Learn More

Upcoming Events

November 20, 2018 • 8:30am EST

Corporate Update Conference Call & Webcast

December 5, 2018 • 9:30am EST

Special Meeting of Stockholders

View All Events

Immune Pharmaceuticals, Inc.